YUMAB
Mark Identification

YUMAB

Serial Number

79191669

Filing Date

Apr 25, 2016

Registration Date

Jul 11, 2017

Trademark by

YUMAB GMBH

Active Trademark

Classification Information

[ Monoclonal antibodies for quantitative determination of leukocyte subsets other than for medical purposes; chemicals components being biochemicals for producing radio-labelled monoclonal antibodies for industrial or scientific purposes; proteins for detecting antibodies other than for medical purposes; ] monoclonal antibodies for industrial use; monoclonal antibody reagents, other than for medical use; antigens and antibodies being biochemicals for diagnostic use not for medical purposes; immunological antibodies, being biochemicals, other than for medical use; tagged antibodies being biochemicals for scientific use; [ monoclonal antibodies for qualitative determination of leukocyte subsets other than for medical purposes; linkage compounds being biochemicals for scientific purposes for coupling of radioactive compounds to antibodies; reagents for use in the development of hybridoma antibodies other than for medical or veterinary purposes; ] biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; proteins for binding antibodies other than for medical purposes; monoclonal antibodies for scientific use; [ linkage compounds being biochemicals for scientific purposes for coupling antibodies to radio nuclides; monoclonal antibodies for research into haematopoietic systems other than for medical purposes; ] reagents for use in development of monoclonal antibodies other than for medical or veterinary purposes; [ components for producing radio-labelled antibody fragments for industrial or scientific purposes being biochemicals; ] tagged antibodies being biochemicals for laboratory use; reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) other than for medical or veterinary purposes comprised primarily of biochemicals

Chemicals

Antibodies, antibody fragments and antigens in the nature of pharmaceuticals for the treatment of cancer, haematopoietic diseases, autoimmune diseases, neurodegenerative diseases, metabolic diseases, eye diseases, infections, diseases of heart and circulation, bone diseases, transplantation, sepsis, intoxications, and adverse drug reactions

Pharmaceuticals

Scientific research; technological services being antibody engineering and design; industrial analysis and research services in the nature of laboratory research and new product design services relating to the production of monoclonal antibodies

Computer and Scientific